Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Fentanyl transdermal patch

  • News

Executive Summary

Agreement between Cygnus and Anaquest gives latter exclusive North American marketing rights. Cygnus has been developing the patch for the past 18 months, and Anaquest plans to begin clinical in February 1989. The 24-hour patch product is expected to be used for "post operative pain management and relief for terminally ill patients suffering severe chronic pain." Alza filed an NDA for its fentanyl patch product in December 1987.

Agreement between Cygnus and Anaquest gives latter exclusive North American marketing rights. Cygnus has been developing the patch for the past 18 months, and Anaquest plans to begin clinical in February 1989. The 24-hour patch product is expected to be used for "post operative pain management and relief for terminally ill patients suffering severe chronic pain." Alza filed an NDA for its fentanyl patch product in December 1987.

Table

View full table

Tags:
Latest Headlines

Pharma Can Pursue Claims Against Providers For 340B Duplicate Discounts In Medicaid Managed Care, HRSA Says

The Aspirin Test For AI?

Mary Beth Clarke, CDER Exec Programs Office Director And Generic User Fee Shepherd, Will Retire

Rx Advertising: Interchangeability Doesn’t Mean Clinical Superiority To Other Biosimilars, FDA Says

See All
UsernamePublicRestriction

Register

PS014598

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By